CA3121528A1 - Anellosomes and methods of use - Google Patents
Anellosomes and methods of use Download PDFInfo
- Publication number
- CA3121528A1 CA3121528A1 CA3121528A CA3121528A CA3121528A1 CA 3121528 A1 CA3121528 A1 CA 3121528A1 CA 3121528 A CA3121528 A CA 3121528A CA 3121528 A CA3121528 A CA 3121528A CA 3121528 A1 CA3121528 A1 CA 3121528A1
- Authority
- CA
- Canada
- Prior art keywords
- acid sequence
- orf1
- nucleic acid
- sequence
- anellosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 177
- 150000007523 nucleic acids Chemical group 0.000 claims description 515
- 230000002068 genetic effect Effects 0.000 claims description 376
- 210000004027 cell Anatomy 0.000 claims description 369
- 102000039446 nucleic acids Human genes 0.000 claims description 358
- 108020004707 nucleic acids Proteins 0.000 claims description 358
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 258
- 239000012636 effector Substances 0.000 claims description 233
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 224
- 229920001184 polypeptide Polymers 0.000 claims description 223
- 241001339993 Anelloviridae Species 0.000 claims description 221
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 claims description 207
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 207
- 101000833492 Homo sapiens Jouberin Proteins 0.000 claims description 203
- 102100024407 Jouberin Human genes 0.000 claims description 203
- 125000003729 nucleotide group Chemical group 0.000 claims description 202
- 239000002773 nucleotide Substances 0.000 claims description 200
- 108090000623 proteins and genes Proteins 0.000 claims description 142
- 102000004169 proteins and genes Human genes 0.000 claims description 134
- 235000018102 proteins Nutrition 0.000 claims description 129
- 150000001413 amino acids Chemical class 0.000 claims description 122
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 claims description 109
- 101710130262 Probable Vpr-like protein Proteins 0.000 claims description 109
- 239000008194 pharmaceutical composition Substances 0.000 claims description 64
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 53
- -1 TAIP Proteins 0.000 claims description 47
- 101150097234 ORF2/3 gene Proteins 0.000 claims description 44
- 101100028137 Torque teno virus (isolate Human/Finland/Hel32/2002) ORF1/1 gene Proteins 0.000 claims description 44
- 101100028140 Torque teno virus (isolate Human/Finland/Hel32/2002) ORF1/2 gene Proteins 0.000 claims description 44
- 241000700605 Viruses Species 0.000 claims description 44
- 108020004414 DNA Proteins 0.000 claims description 39
- 235000001014 amino acid Nutrition 0.000 claims description 36
- 229940024606 amino acid Drugs 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 36
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 30
- 230000003612 virological effect Effects 0.000 claims description 30
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 26
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 claims description 24
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 claims description 24
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 claims description 24
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 claims description 24
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 claims description 24
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 claims description 24
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 claims description 24
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 claims description 24
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 claims description 24
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 claims description 24
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 claims description 24
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 claims description 24
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 claims description 24
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 claims description 24
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 claims description 24
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 claims description 24
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 claims description 24
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 claims description 24
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 claims description 24
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 claims description 24
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 claims description 24
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 claims description 24
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 claims description 24
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 claims description 24
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 claims description 24
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 claims description 24
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 claims description 24
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 claims description 24
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 claims description 24
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 claims description 24
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 claims description 24
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 claims description 24
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 claims description 24
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 claims description 24
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 claims description 24
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 claims description 24
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 claims description 24
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 claims description 24
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 claims description 24
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 claims description 24
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 claims description 24
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 claims description 24
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 claims description 24
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 claims description 24
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 claims description 24
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 claims description 24
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 claims description 24
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 claims description 24
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 claims description 24
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 claims description 24
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 claims description 24
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 claims description 24
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 23
- 230000001225 therapeutic effect Effects 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 239000002679 microRNA Substances 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 18
- 210000004899 c-terminal region Anatomy 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 108091070501 miRNA Proteins 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 15
- 210000004962 mammalian cell Anatomy 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 210000005260 human cell Anatomy 0.000 claims description 13
- 239000011541 reaction mixture Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 239000000356 contaminant Substances 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 230000002458 infectious effect Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 230000001973 epigenetic effect Effects 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 108020004638 Circular DNA Proteins 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 108020005198 Long Noncoding RNA Proteins 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 6
- 230000001472 cytotoxic effect Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 230000010076 replication Effects 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000010643 digestive system disease Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 5
- 239000012642 immune effector Substances 0.000 claims description 5
- 208000026278 immune system disease Diseases 0.000 claims description 5
- 229940121354 immunomodulator Drugs 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 4
- 108020005544 Antisense RNA Proteins 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 4
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 230000008836 DNA modification Effects 0.000 claims description 4
- 108020005004 Guide RNA Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 230000002860 competitive effect Effects 0.000 claims description 4
- 239000003184 complementary RNA Substances 0.000 claims description 4
- 230000034994 death Effects 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 239000000138 intercalating agent Substances 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 108020004017 nuclear receptors Proteins 0.000 claims description 4
- 108091008819 oncoproteins Proteins 0.000 claims description 4
- 102000027450 oncoproteins Human genes 0.000 claims description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 230000009145 protein modification Effects 0.000 claims description 4
- 238000001243 protein synthesis Methods 0.000 claims description 4
- 108091006082 receptor inhibitors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 230000014616 translation Effects 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 210000005229 liver cell Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 238000000424 optical density measurement Methods 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 79
- 208000029265 Type 1 interferonopathy Diseases 0.000 claims 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 157
- 238000012217 deletion Methods 0.000 description 145
- 230000037430 deletion Effects 0.000 description 145
- 230000027455 binding Effects 0.000 description 75
- 238000003780 insertion Methods 0.000 description 52
- 230000037431 insertion Effects 0.000 description 52
- 238000006467 substitution reaction Methods 0.000 description 52
- 108700026244 Open Reading Frames Proteins 0.000 description 50
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 34
- 239000004475 Arginine Substances 0.000 description 30
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 30
- 108700026226 TATA Box Proteins 0.000 description 29
- 238000007385 chemical modification Methods 0.000 description 27
- 230000035772 mutation Effects 0.000 description 27
- 230000009144 enzymatic modification Effects 0.000 description 26
- 230000002103 transcriptional effect Effects 0.000 description 26
- 101710189078 Helicase Proteins 0.000 description 25
- 108091034057 RNA (poly(A)) Proteins 0.000 description 25
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 25
- 101710172711 Structural protein Proteins 0.000 description 25
- 230000004076 epigenetic alteration Effects 0.000 description 25
- 102000040430 polynucleotide Human genes 0.000 description 25
- 108091033319 polynucleotide Proteins 0.000 description 25
- 239000002157 polynucleotide Substances 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 22
- 241000960387 Torque teno virus Species 0.000 description 19
- 230000001717 pathogenic effect Effects 0.000 description 19
- 102000053602 DNA Human genes 0.000 description 13
- 108020004682 Single-Stranded DNA Proteins 0.000 description 13
- 241000332807 TTV-like mini virus Species 0.000 description 13
- 241001339888 Alphatorquevirus Species 0.000 description 12
- 238000004806 packaging method and process Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108090000565 Capsid Proteins Proteins 0.000 description 8
- 102100023321 Ceruloplasmin Human genes 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 210000000234 capsid Anatomy 0.000 description 7
- 210000004779 membrane envelope Anatomy 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000003362 replicative effect Effects 0.000 description 7
- 230000004568 DNA-binding Effects 0.000 description 6
- 108091005461 Nucleic proteins Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000204031 Mycoplasma Species 0.000 description 5
- 101710150114 Protein rep Proteins 0.000 description 5
- 101710152114 Replication protein Proteins 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091030087 Initiator element Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241001068263 Replication competent viruses Species 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241001339887 Betatorquevirus Species 0.000 description 3
- 241001339886 Gammatorquevirus Species 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 108091092724 Noncoding DNA Proteins 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 101150068419 ORF 1 gene Proteins 0.000 description 2
- 101710113540 ORF2 protein Proteins 0.000 description 2
- 101710090523 Putative movement protein Proteins 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241000701368 Alphafusellovirus Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241001206543 Ampullavirus Species 0.000 description 1
- 241000157874 Ascovirus Species 0.000 description 1
- 241000405758 Betapartitivirus Species 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000702216 Cystovirus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000723722 Furovirus Species 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 241000868843 Globulovirus Species 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 241000724309 Hordeivirus Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000702377 Inovirus Species 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000701372 Iridovirus Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000702321 Microvirus Species 0.000 description 1
- 241001494793 Nanovirus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241000723848 Tobamovirus Species 0.000 description 1
- 241000723717 Tobravirus Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940124642 endogenous agent Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00051—Methods of production or purification of viral material
- C12N2750/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862778841P | 2018-12-12 | 2018-12-12 | |
| US201862778866P | 2018-12-12 | 2018-12-12 | |
| US62/778,841 | 2018-12-12 | ||
| US62/778,866 | 2018-12-12 | ||
| PCT/US2019/065995 WO2020123816A2 (en) | 2018-12-12 | 2019-12-12 | Anellosomes and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3121528A1 true CA3121528A1 (en) | 2020-06-18 |
Family
ID=69165586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3121528A Pending CA3121528A1 (en) | 2018-12-12 | 2019-12-12 | Anellosomes and methods of use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220042042A1 (enExample) |
| EP (1) | EP3894570A2 (enExample) |
| JP (2) | JP2022513797A (enExample) |
| KR (1) | KR20210131310A (enExample) |
| CN (1) | CN113631716A (enExample) |
| AU (1) | AU2019397058A1 (enExample) |
| BR (1) | BR112021011124A2 (enExample) |
| CA (1) | CA3121528A1 (enExample) |
| IL (1) | IL283782A (enExample) |
| MX (1) | MX2021006977A (enExample) |
| WO (1) | WO2020123816A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4337235A4 (en) * | 2021-05-12 | 2025-07-02 | Flagship Pioneering Innovations V Inc | ANELLOVECTORS AND METHODS OF USE |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018201160A1 (en) | 2017-04-28 | 2018-11-01 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| CA3056801A1 (en) | 2017-04-28 | 2018-11-01 | Agrospheres, Inc. | Compositions and methods for the encapsulation and scalable delivery of agrochemicals |
| MX2020003074A (es) | 2017-09-25 | 2020-09-14 | Agrospheres Inc | Composiciones y metodos para la produccion y la administracion expansible de productos biologicos. |
| WO2020123795A2 (en) * | 2018-12-12 | 2020-06-18 | Flagship Pioneering Innovations V, Inc. | Anellosomes for delivering protein replacement therapeutic modalities |
| WO2021252955A1 (en) * | 2020-06-12 | 2021-12-16 | Flagship Pioneering Innovations V, Inc. | Tandem anellovirus constructs |
| CA3206361A1 (en) * | 2020-12-23 | 2022-06-30 | Flagship Pioneering Innovations V, Inc. | In vitro assembly of anellovirus capsids enclosing rna |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| WO2025080985A1 (en) | 2023-10-13 | 2025-04-17 | Flagship Pioneering Innovations V, Inc. | Tissue specific anellovector delivery |
| WO2025160409A1 (en) | 2024-01-26 | 2025-07-31 | Flagship Pioneering Innovations V, Inc. | Viral vectors for modulating vegf function |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395472B1 (en) * | 1999-02-05 | 2002-05-28 | Abbott Laboratories | Methods of utilizing the TT virus |
| CA2932479A1 (en) * | 2013-12-12 | 2015-06-18 | The Rockefeller University | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
| KR20200038236A (ko) * | 2017-06-13 | 2020-04-10 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 큐론을 포함하는 조성물 및 그의 용도 |
| CA3119339A1 (en) * | 2018-12-12 | 2020-06-18 | Flagship Pioneering Innovations V, Inc. | Anellosomes for delivering intracellular therapeutic modalities |
| WO2020123795A2 (en) * | 2018-12-12 | 2020-06-18 | Flagship Pioneering Innovations V, Inc. | Anellosomes for delivering protein replacement therapeutic modalities |
| BR112021009379A2 (pt) * | 2018-12-12 | 2021-08-17 | Flagship Pioneering Innovations V, Inc | anelossomos para entrega de modalidades terapêuticas secretadas |
-
2019
- 2019-12-12 MX MX2021006977A patent/MX2021006977A/es unknown
- 2019-12-12 US US17/413,392 patent/US20220042042A1/en active Pending
- 2019-12-12 BR BR112021011124A patent/BR112021011124A2/pt unknown
- 2019-12-12 EP EP19836738.5A patent/EP3894570A2/en active Pending
- 2019-12-12 JP JP2021533528A patent/JP2022513797A/ja not_active Withdrawn
- 2019-12-12 CA CA3121528A patent/CA3121528A1/en active Pending
- 2019-12-12 WO PCT/US2019/065995 patent/WO2020123816A2/en not_active Ceased
- 2019-12-12 KR KR1020217021777A patent/KR20210131310A/ko not_active Ceased
- 2019-12-12 AU AU2019397058A patent/AU2019397058A1/en active Pending
- 2019-12-12 CN CN201980091082.6A patent/CN113631716A/zh active Pending
-
2021
- 2021-06-07 IL IL283782A patent/IL283782A/en unknown
-
2024
- 2024-05-07 JP JP2024075373A patent/JP2024099834A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4337235A4 (en) * | 2021-05-12 | 2025-07-02 | Flagship Pioneering Innovations V Inc | ANELLOVECTORS AND METHODS OF USE |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021011124A2 (pt) | 2022-03-15 |
| US20220042042A1 (en) | 2022-02-10 |
| CN113631716A (zh) | 2021-11-09 |
| JP2022513797A (ja) | 2022-02-09 |
| JP2024099834A (ja) | 2024-07-25 |
| WO2020123816A2 (en) | 2020-06-18 |
| IL283782A (en) | 2021-07-29 |
| MX2021006977A (es) | 2021-10-13 |
| WO2020123816A3 (en) | 2020-08-06 |
| KR20210131310A (ko) | 2021-11-02 |
| AU2019397058A1 (en) | 2021-06-10 |
| EP3894570A2 (en) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3121528A1 (en) | Anellosomes and methods of use | |
| CA3119531A1 (en) | Anellosomes for delivering secreted therapeutic modalities | |
| CA3119814A1 (en) | Anellosomes for delivering protein replacement therapeutic modalities | |
| CA3066750A1 (en) | Compositions comprising curons and uses thereof | |
| FI118538B (fi) | Menetelmä geeniterapiassa käytettävien adenoviraalisten eläinperäisten vektoreiden valmistamiseksi | |
| CA3119339A1 (en) | Anellosomes for delivering intracellular therapeutic modalities | |
| JP2025148444A (ja) | 未成熟終止コドン媒介障害を処置するための方法および組成物 | |
| JP2022115976A (ja) | ユートロフィン遺伝子を標的とした筋ジストロフィーの治療方法 | |
| CN110393791B (zh) | hnRNPA2B1的抗感染作用及其应用 | |
| CN113195719A (zh) | 用于增加蛋白质表达和/或治疗单倍剂量不足症的方法及组合物 | |
| AU2021372533A1 (en) | Chicken anemia virus (cav)-based vectors | |
| JPH10506018A (ja) | 不活化ＩＶａ２遺伝子を有する欠陥組換えアデノウィルス | |
| WO2022140560A1 (en) | In vitro assembly of anellovirus capsids enclosing rna | |
| CN114423868B (zh) | 用于将大载量基因和蛋白质递送到人细胞中的原核-真核杂交病毒载体 | |
| KR20230041686A (ko) | 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도 | |
| Wang et al. | Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein | |
| CN115885040A (zh) | 可用于治疗cdkl5缺乏症（cdd）的组合物 | |
| WO2021156831A1 (en) | Mirna-485 inhibitor for gene upregulation | |
| EP4048798B1 (en) | Adenovirus comprising a modified adenovirus hexon protein | |
| EP4029515B1 (en) | Anti-infection effects of hnrnpa2b1 and use thereof | |
| EP2128261B1 (en) | A recombinant adenovirus comprising recombinant khp53 gene and preparation method and uses thereof | |
| JP2023513189A (ja) | 筋萎縮性側索硬化症（ａｌｓ）を治療するためのｍｉｒｎａ－４８５阻害剤の使用 | |
| CN115838725B (zh) | 在哺乳动物心脏中特异性启动基因的启动子序列及其应用 | |
| US20250332284A1 (en) | Modified plant virus system for delivery of nucleic acids into mammalian cells | |
| WO2025018299A1 (ja) | 血管平滑筋細胞指向カプシド、アデノ随伴ウイルスベクター、医薬組成物、治療方法、核酸導入方法、及びカプシド製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220726 |
|
| EEER | Examination request |
Effective date: 20220726 |
|
| EEER | Examination request |
Effective date: 20220726 |
|
| EEER | Examination request |
Effective date: 20220726 |
|
| EEER | Examination request |
Effective date: 20220726 |